CStone

News

Akeso and CStone secure China clearances for next-generation...

Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.

News

CStone gets a win for sugemalimab in oesophageal cancer

Suzhou-based CStone Pharmaceuticals' checkpoint inhibitor sugemalimab has proved effective in a trial as a first-line therapy for oesophageal cancer, setting up a regulatory filing in China

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Pfizer picks up rights to CStone's cancer immunotherapy suge...

Pfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration that will see the big US pharma gain rights to the company’s immunoth

Akeso and CStone secure China clearances for next-generation...

CStone gets a win for sugemalimab in oesophageal cancer

Pfizer picks up rights to CStone's cancer immunotherapy suge...

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks